Lyme Disease: Has Big Pharma Stopped The Clock On A Cure?

Though vastly underreported, new cases of Lyme in the US total more than 300,000 a year; its incidence now exceeds infections for far more visible conditions like HIV. A higher profile for Lyme is hobbled by a slow and distorted institutional response, especially among clinicians who disagree on whether Lyme is one disease or a complex constellation of many – much like cancer, but without the commitment.

Tick_1200

The fight against infectious disease presents a revealing truth to medical practice: as hard as it is to understand the intricate variations in the life cycle of a single pathogen, it is harder still to understand the larger effects from that pathogen’s relationship to its even more complex human hosts. Ultimate success in finding new treatments depends on how well researchers relate to the environmental factors that shape – and often distort – interactions between the pathogen and the patient. These include the mode of transmission, the distinctiveness of symptoms and the capacity to identify and diagnose the illness in normal clinical practice. Remove these from the physician playbook and you have the makings of a crisis in the administration of care – one where a transmissible condition is known to exist but for which there is no accompanying consensus on a single source of contagion or on the various ways it presents in the human population.

Medical practice now has that crisis – and it’s happening in real time. The culprit is Lyme disease, which since...

More from Innovation

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.